|Newsletter - June 2014
82nd Congress of the European Atherosclerosis Society, 31 May-3 June, Madrid, Spain
What made the news for PCSK9?
New resources available
The Forum is building up extensive resources for clinicians. This includes a series of video interviews with experts in this field, including:
To view the videos click here
PCSK9 inhibition: From genetics to patients (slide resource)
This comprehensive slide set prepared by Professor John Chapman, provides a comprehensive introduction to the importance of new therapeutic targets in the reduction of LDL-cholesterol.
To view the slide set click here
More than 60 global experts now join PCSK9 Forum
More than 60 experts have now joined the editorial team who are contributing to the PCSK9 Education and Research Forum initiative. The group includes leading researchers from Europe, North America, Asia and Latin America.
To view the Editorial Board, click here.
Send an invitation to join PCSK9 Forum to your colleagues, click here for the invite link
In the next 3 years the PCSK9 Education and Research Forum will become a major, globally-recognised source of independent, scientific knowledge of the critical importance of PCSK9 inhibition in the search for treatments which promise to transform the prognosis of millions of people with atherosclerotic dyslipidaemia.
Our response to this challenge
Established by leading researchers as a not-for-profit organisation, the PCSK9 Education and Research Forum will provide healthcare professionals with open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; and, an extensive library of accredited educational materials tailored to the differing needs of a spectrum of audiences. As a result, the Forum will expand awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.
Our partnership and outreach
Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum will reach out to academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum will establish educational partnerships with such organisations through jointly sponsored symposia as well as accredited research and educational programmes.